[Articles] Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial
March 13, 2016
- The Lancet 387, 10022 (2016)
Author: Ian J Jacobs, Usha Menon, Andy Ryan, Aleksandra Gentry-Maharaj, Matthew Burnell, Jatinderpal K Kalsi, Nazar N Amso, Sophia Apostolidou, Elizabeth Benjamin, Derek Cruickshank, Danielle N Crump, Susan K Davies, Anne Dawnay, Stephen Dobbs, Gwendolen Fletcher, Jeremy Ford, Keith Godfrey, Richard Gunu, Mariam Habib, Rachel Hallett, Jonathan Herod, Howard Jenkins, Chloe Karpinskyj, Simon Leeson, Sara J Lewis, William R Liston, Alberto Lopes, Tim Mould, John Murdoch, David Oram, Dustin J Rabideau, Karina Reynolds, Ian Scott, Mourad W Seif, Aarti Sharma, Naveena Singh, Julie Taylor, Fiona Warburton, Martin Widschwendter, Karin Williamson, Robert Woolas, Lesley Fallowfield, Alistair J McGuire, Stuart Campbell, Mahesh Parmar, Steven J Skates
Although the mortality reduction was not significant in the primary analysis, we noted a significant mortality reduction with MMS when prevalent cases were excluded. We noted encouraging evidence of a mortality reduction in years 7–14, but further follow-up is needed before firm conclusions can be reached on the efficacy and cost-effectiveness of ovarian cancer screening.